Skip to main content
Figure 2 | BMC Neurology

Figure 2

From: Clinical baseline factors predict response to natalizumab: their usefulness in patient selection

Figure 2

Clinical effect of natalizumab in patients treated with 12 or 24 monthly infusions. a) Changes in annualized relapse rate among the pre-treatment year and the follow-up, *P < 0.0001; b) Changes in mean EDSS over time *P < 0.0001, §P = 0.009 (Friedman test), °P < 0.05 (Dunn’s post test); c) Percentage of patients with improvement by at least 1 point, worsening by at least one point, or stable EDSS score in the first year of treatment compared to baseline and d) in the second year; e) Percentage of disease-free patients in the first year and f) in the second year of treatment; g) percentage of patients with BET = 1 within the first year of treatment.

Back to article page